Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Ovarian Cancer
Do you offer PARP inhibitor maintenance therapy to stage IC high grade serous ovarian cancer patients?
Related Questions
Does the PFS and OS data presented at ESMO 2025 for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
How do you manage patients with germline BRCA mutations who have STIC lesions found at the time of risk-reducing BSO?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
How do you logistically incorporate a "scope and score" of a patient with newly diagnosed advanced ovarian cancer into a busy OR schedule?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
For a borderline ovarian tumor that has been resected with BSO and hysterectomy, would you consider endocrine therapy if found to be ER-positive?
